← Back to Search

Monoclonal Antibodies

Part B: maridebart cafraglutide for Obesity

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial aims to test if AMG 133 is safe and can be tolerated by people with obesity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Part C: maridebart cafraglutideExperimental Treatment1 Intervention
Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
Group II: Part B: maridebart cafraglutideExperimental Treatment1 Intervention
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Group III: Part A: maridebart cafraglutideExperimental Treatment1 Intervention
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Group IV: Part A: PlaceboPlacebo Group1 Intervention
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Group V: Part B: PlaceboPlacebo Group1 Intervention
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
maridebart cafraglutide
2020
Completed Phase 1
~150

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,420 Previous Clinical Trials
1,382,840 Total Patients Enrolled
10 Trials studying Obesity
1,051 Patients Enrolled for Obesity
MDStudy DirectorAmgen
961 Previous Clinical Trials
928,755 Total Patients Enrolled
6 Trials studying Obesity
867 Patients Enrolled for Obesity
~22 spots leftby Sep 2025